271 related articles for article (PubMed ID: 34583970)
21. Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!
Di Noia V; Pimpinelli F; Renna D; Maccallini MT; Gariazzo L; Cosimati A; Campo F; Sperandio E; Pellini R; Giannarelli D; Cognetti F
Eur J Cancer; 2022 Apr; 165():169-173. PubMed ID: 35245863
[TBL] [Abstract][Full Text] [Related]
22. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
[TBL] [Abstract][Full Text] [Related]
23. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.
Levy I; Wieder-Finesod A; Litchevsky V; Biber A; Indenbaum V; Olmer L; Huppert A; Mor O; Goldstein M; Levin EG; Hod T; Cohen C; Lustig Y; Rahav G
Clin Microbiol Infect; 2021 Dec; 27(12):1851-1855. PubMed ID: 34438069
[TBL] [Abstract][Full Text] [Related]
25. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.
Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M
Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593
[TBL] [Abstract][Full Text] [Related]
26. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
[TBL] [Abstract][Full Text] [Related]
27. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
Gavriatopoulou M; Terpos E; Malandrakis P; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
Br J Haematol; 2022 Jan; 196(2):356-359. PubMed ID: 34528249
[TBL] [Abstract][Full Text] [Related]
28. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.
Stampfer SD; Goldwater MS; Jew S; Bujarski S; Regidor B; Daniely D; Chen H; Xu N; Li M; Green T; Fung E; Aquino E; Swift R; Eshaghian S; Preugschat K; Feinstein AJ; Spektor TM; Berenson JR
Leukemia; 2021 Dec; 35(12):3534-3541. PubMed ID: 34326466
[TBL] [Abstract][Full Text] [Related]
29. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
Peled Y; Ram E; Lavee J; Segev A; Matezki S; Wieder-Finesod A; Halperin R; Mandelboim M; Indenbaum V; Levy I; Sternik L; Raanani E; Afek A; Kreiss Y; Lustig Y; Rahav G
J Heart Lung Transplant; 2022 Feb; 41(2):148-157. PubMed ID: 34565682
[TBL] [Abstract][Full Text] [Related]
30. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
Gastinne T; Le Bourgeois A; Coste-Burel M; Guillaume T; Peterlin P; Garnier A; Imbert BM; Drumel T; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Tessoulin B; Jullien M; Vanthygem S; Béné MC; Moreau P; Le Gouill S; Chevallier P
Br J Haematol; 2022 Jan; 196(2):360-362. PubMed ID: 34476803
[No Abstract] [Full Text] [Related]
31. 18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting.
Karunathilake RP; Kumara RA; Karunathilaka A; Wazil AWM; Nanayakkara N; Bandara CK; Abeysekera RA; Noordeen F; Gawarammana IB; Ratnatunga CN
BMC Nephrol; 2024 May; 25(1):176. PubMed ID: 38778281
[TBL] [Abstract][Full Text] [Related]
32. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.
Levin EG; Lustig Y; Cohen C; Fluss R; Indenbaum V; Amit S; Doolman R; Asraf K; Mendelson E; Ziv A; Rubin C; Freedman L; Kreiss Y; Regev-Yochay G
N Engl J Med; 2021 Dec; 385(24):e84. PubMed ID: 34614326
[TBL] [Abstract][Full Text] [Related]
33. Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis.
Kim DK; Jung SW; Moon JY; Jeong KH; Hwang HS; Kim JS; Lee SH; Kang SY; Kim YG
Front Immunol; 2022; 13():894700. PubMed ID: 35734170
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study.
Salmerón Ríos S; Cortés Zamora EB; Avendaño Céspedes A; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Mas Romero M; Tabernero Sahuquillo MT; Blas Señalada JJ; Murillo Romero A; García Nogueras I; Estrella Cazalla JD; Andrés-Pretel F; Lauschke VM; Stebbing J; Abizanda P
J Am Geriatr Soc; 2022 Mar; 70(3):650-658. PubMed ID: 34894403
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 BNT162b2 vaccine-induced humoral response and reactogenicity in individuals with prior COVID-19 disease.
Kelsen SG; Braverman AS; Aksoy MO; Hayman JA; Patel PS; Rajput C; Zhao H; Fisher SG; Ruggieri MR; Gentile NT
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35019861
[TBL] [Abstract][Full Text] [Related]
36. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
[TBL] [Abstract][Full Text] [Related]
37. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
J Hematol Oncol; 2021 May; 14(1):81. PubMed ID: 34001183
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy.
Sugihara K; Wakiya R; Shimada H; Kameda T; Nakashima S; Kato M; Miyagi T; Mizusaki M; Mino R; Nomura Y; Inoo M; Kadowaki N; Dobashi H
Intern Med; 2022 Jul; 61(13):1953-1958. PubMed ID: 35466168
[TBL] [Abstract][Full Text] [Related]
39. Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers.
Debes AK; Xiao S; Colantuoni E; Egbert ER; Caturegli P; Gadala A; Milstone AM
JAMA Intern Med; 2021 Dec; 181(12):1660-1662. PubMed ID: 34398173
[TBL] [Abstract][Full Text] [Related]
40. Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges.
Faro-Viana J; Bergman ML; Gonçalves LA; Duarte N; Coutinho TP; Borges PC; Diwo C; Castro R; Matoso P; Malheiro V; Brennand A; Kosack L; Akpogheneta O; Figueira JM; Cardoso C; Casaca AM; Alves PM; Nunes T; Penha-Gonçalves C; Demengeot J
Nat Commun; 2022 Jan; 13(1):140. PubMed ID: 35013258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
